Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 394,548
  • Shares Outstanding, K 40,260
  • Annual Sales, $ 890 K
  • Annual Income, $ -21,870 K
  • 36-Month Beta 2.28
  • Price/Sales 441.49
  • Price/Cash Flow 0.00
  • Price/Book 4.10

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.25 +86.67%
on 06/22/17
10.26 -4.48%
on 07/20/17
+4.80 (+96.00%)
since 06/21/17
3-Month
4.55 +115.38%
on 06/16/17
10.26 -4.48%
on 07/20/17
+4.60 (+88.46%)
since 04/21/17
52-Week
2.42 +304.96%
on 07/27/16
10.26 -4.48%
on 07/20/17
+7.32 (+295.16%)
since 07/21/16

Most Recent Stories

More News
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

Pivotal Phase 3 clinical trial is planned to commence in early 2018

ABEO : 9.80 (+0.51%)
Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6%

Abeona Therapeutics Inc. (ABEO) moved big last session, as the company saw its shares rise over 10% on the day.

ENZ : 11.35 (-1.05%)
ABEO : 9.80 (+0.51%)
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has...

ABEO : 9.80 (+0.51%)
Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced President and CEO,...

ABEO : 9.80 (+0.51%)
Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has...

ABEO : 9.80 (+0.51%)
Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

Abeona's Third Gene Therapy Program to Receive FDA Orphan Designation

ABEO : 9.80 (+0.51%)
Abeona Therapeutics to Present at Multiple Upcoming Conferences

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced that members of the management...

ABEO : 9.80 (+0.51%)
Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced financial results for...

ABEO : 9.80 (+0.51%)
Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced Australian regulatory...

ABEO : 9.80 (+0.51%)
Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that data from...

ABEO : 9.80 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Support & Resistance

2nd Resistance Point 10.37
1st Resistance Point 10.08
Last Price 9.80
1st Support Level 9.53
2nd Support Level 9.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.